Aligos Therapeutics, Inc. (ALGS) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 3 Buy, 2 Hold.
The consensus price target is $20.00, representing an upside of 133.9% from the current price $8.55.
Analysts estimate Earnings Per Share (EPS) of $-10.09 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-20.94 vs est $-10.09 (missed -107.5%). 2025: actual $-2.45 vs est $-9.06 (beat +73%). Analyst accuracy: 0%.
ALGS Stock — 12-Month Price Forecast
$20.00
▲ +133.92% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Aligos Therapeutics, Inc., the price target is $20.00.
The average price target represents a +133.92% change from the last price of $8.55.
ALGS Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Aligos Therapeutics, Inc. in the past 3 months
EPS Estimates — ALGS
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$20.94
vs Est –$10.09
▼ 51.8% off
2025
Actual –$2.45
vs Est –$9.06
▲ 269.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ALGS
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.004B
vs Est $0.004B
▲ 5.4% off
2025
Actual $0.002B
vs Est $0.002B
▼ 12.1% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
